Who is sponsoring NCT06172634?

NCT06172634 is sponsored by Soonchunhyang University Hospital.

What drugs are being tested in NCT06172634?

Interventions in NCT06172634: dentritic cell infusion and immunecheckpoint inhibitor.

What condition does NCT06172634 study?

NCT06172634 studies Pancreas Cancer.

Is NCT06172634 still recruiting?

NCT06172634 is currently status unknown. Last updated 15 December 2023.

Last reviewed 2023-12-15 · How we verify

NCT06172634: DICI_PC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Single-center Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow-derived DCs(CellgramDC-WT1) and Immune Checkpoint Inhibitors in Patients With Metastatic Pancreatic Cancer Who Have Failed First-line or More Standard Chemotherapy

Status unknown Phase 1, PHASE2 Last updated 15 December 2023

What this trial tests

Phase 1, PHASE2 trial testing dentritic cell infusion and immunecheckpoint inhibitor in Pancreas Cancer in 10 participants. Status unknown.

Timeline

1 March 2024

Primary endpoint
31 December 2024

31 December 2025

Quick facts

Lead sponsor	Soonchunhyang University Hospital
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	1 March 2024
Primary completion	31 December 2024
Estimated completion	31 December 2025

Drugs / interventions tested

dentritic cell infusion and immunecheckpoint inhibitor — full drug profile →

Conditions studied

Pancreas Cancer — all drugs for Pancreas Cancer →

Sponsor

Soonchunhyang University Hospital

Who can join

Adults 19 to 80, any sex, with Pancreas Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the safety and effectiveness of immune cell therapy using autologous bone marrow-derived dendritic cells and immune checkpoint inhibitors in patients with metastatic pancreatic cancer who have failed at least one standard anticancer treatment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Trial watch: anticancer vaccination with dendritic cells.
Borges F, Laureano RS, Vanmeerbeek I, Sprooten J, et al · · 2024 · cited 18× · PMID 39398476 · DOI 10.1080/2162402x.2024.2412876

Verify or expand the search:

Other recruiting trials for Pancreas Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07230509 — Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate · Phase 2 · recruiting
NCT06926075 — Early Phase Study of KESONOTIDE™in Participants With Solid Tumours · Phase 1, PHASE2 · recruiting
NCT07179692 — CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors · Phase 1 · recruiting
NCT07132541 — Saleh's Technique for Pancreaticojejunostomy (Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate) · Phase 1 · recruiting

Other Soonchunhyang University Hospital trials

Trials by the same sponsor.

NCT07213596 — Virtual Reality Treatment for Trauma Related to COVID-19 Infection · NA · not yet recruiting
NCT06950489 — Tegoprazan and Amoxicillin Dual Therapy · recruiting
NCT06682533 — Tegoprazan- Versus PPI-based H. Pylori Eradication · recruiting
NCT06684860 — RUT vs. Molecular Testing for H. Pylori · recruiting
NCT06369896 — Digital Single-operator Cholangioscopy and Intraductal Ultrasound for Nonicteric Biliary Strictures · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06172634 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Soonchunhyang University Hospital
Last refreshed: 15 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06172634.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing